Yun Feiyu, Yun Mark M, Li Xin, Yun Sheng
Stem Cell Centre, Affiliated Hospital of Inner Mongolia Medical University, No. 1 Tongdao Beijie, Inner Mongolia, Hohhot, 010050, China.
Fengyuan Biosciences Company, Guangzhou, 510700, China.
Clin Exp Med. 2025 Aug 2;25(1):272. doi: 10.1007/s10238-025-01796-8.
To evaluate the safety and efficacy of modified CIK cells combined with PD-1 antibody in the treatment of refractory non-small cell lung cancer (NSCLC). Fifteen patients with refractory NSCLC who were treated in our hospital were recruited for this clinical study from January 2015 to December 2020. All patients had disease progression after completing routine treatment. Two of 12 patients achieved a partial remission, 6 had stable disease, and 4 had progressive disease. No serious side effects occurred. The percentage of T helper and NKT-like cells in patients increased significantly after immunotherapy (P < 0.05). In addition, the anti-tumor cytokines (IL-2 and INF-γ) increased significantly (P < 0.05). Although the anti-inflammatory cytokine, IL-10, did not change markedly after immunotherapy (P > 0.05), the Karnofsky Performance Scale was improved. Umbilical cord blood mononuclear cells can be induced into NKT-like cells. Induced NKT-like cells had powerful cytotoxicity against tumor cell lines in vitro when combined with PD1 antibody. Immunotherapy also had a significant therapeutic effect on refractory NSCLC with no serious side effects in vivo.
评估经修饰的细胞因子诱导的杀伤细胞（CIK细胞）联合程序性死亡受体1（PD-1）抗体治疗难治性非小细胞肺癌（NSCLC）的安全性和疗效。2015年1月至2020年12月，我院招募了15例难治性NSCLC患者进行这项临床研究。所有患者在完成常规治疗后病情均有进展。12例患者中有2例部分缓解，6例病情稳定，4例病情进展。未发生严重副作用。免疫治疗后患者体内辅助性T细胞和NKT样细胞的比例显著增加（P < 0.05）。此外，抗肿瘤细胞因子（白细胞介素-2和干扰素-γ）显著增加（P < 0.05）。虽然免疫治疗后抗炎细胞因子白细胞介素-10没有明显变化（P > 0.05），但卡氏功能状态评分有所改善。脐带血单个核细胞可诱导分化为NKT样细胞。诱导产生的NKT样细胞与PD1抗体联合时，在体外对肿瘤细胞系具有强大的细胞毒性。免疫治疗对难治性NSCLC也有显著治疗效果，且在体内无严重副作用。
